Close Menu

Janssen

The new NferX platform applies AI to single-cell RNA-seq and clinical data to help pinpoint coronavirus transmission and receptor pathways. 

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.

Analyzing blood transcriptome profiles for non-human primates, researchers narrowed in on a B cell gene expression signature that appears to coincide with protection from SIV, SHIV, or HIV.

Celsius Therapeutics uses single-cell genomic sequencing and informatics to discover new therapies for autoimmune disease and cancer.

Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.

The effort, called FAIRplus, commenced earlier this year with a budget of €8.2 million, funded by the Innovative Medicine Initiative.

Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.

Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.

Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.